Sandbox Reserved 1447

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 12: Line 12:
As VWF plays a role in coagulation, defects in the VWF leads to an inherited bleeding disorder called von Willebrand Disease that affects 0.01%-1% of the population. The disease is characterized by low levels of VWF or a dysfunctional VWF. There are three different forms that vary between the degree of deficiency and function. Type one, the most common form, is distinguished by lower than normal levels of VWF. Type II is distinguished by normal levels, but improper function. The third and most severe type shows little to none activity of VWF. As the von Willebrand Factor acts as a carrier protein for factor VIII, a deficiency can also cause Hemophilia.
As VWF plays a role in coagulation, defects in the VWF leads to an inherited bleeding disorder called von Willebrand Disease that affects 0.01%-1% of the population. The disease is characterized by low levels of VWF or a dysfunctional VWF. There are three different forms that vary between the degree of deficiency and function. Type one, the most common form, is distinguished by lower than normal levels of VWF. Type II is distinguished by normal levels, but improper function. The third and most severe type shows little to none activity of VWF. As the von Willebrand Factor acts as a carrier protein for factor VIII, a deficiency can also cause Hemophilia.
== Interactions ==
== Interactions ==
-
The von Willebrand factor is able to bind to multiple other molecules. Some of these interactions are what cause mutations and loss of functions which leads to von Willebrand Disease. A common molecule that inhibits the platelets activation of VWF is the DNA aptamer ARC1172. The aptamer <scene name='77/778327/Arc1172/2'>binds</scene> to the A1 domain of the VWF which blocks glycoprotein Ib ability to bind. Another DNA aptamer, ARC1779, is also able to bind and inhibit platelet activation. Calcium is another example that disrupts the process of coagulation on the von Willebrand factor. When calcium binds to the A2 domain, creating an <scene name='77/778327/Calcium/1'>A2-Ca2+ complex</scene>, ADAMTS-13 is not able to cleave the VWF.
+
The von Willebrand factor is able to bind to multiple other molecules. Some of these interactions are what cause mutations and loss of functions which leads to von Willebrand Disease. A common molecule that inhibits the platelets activation of VWF is the DNA aptamer ARC1172. The aptamer <scene name='77/778327/Arc1172/2'>binds</scene> to the A1 domain of the VWF which blocks glycoprotein Ib ability to bind <ref>PMID:19913482</ref>. Another DNA aptamer, ARC1779, is also able to bind and inhibit platelet activation. Calcium is another example that disrupts the process of coagulation on the von Willebrand factor. When calcium binds to the A2 domain, creating an <scene name='77/778327/Calcium/1'>A2-Ca2+ complex</scene>, ADAMTS-13 is not able to cleave the VWF.
</StructureSection>
</StructureSection>

Revision as of 18:07, 2 May 2018

This Sandbox is Reserved from Jan 22 through May 22, 2018 for use in the course Biochemistry II taught by Jason Telford at the Maryville University, St. Louis, Missouri, USA. This reservation includes Sandbox Reserved 1446 through Sandbox Reserved 1455.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

von Willebrand Factor

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. Desch KC. Regulation of plasma von Willebrand factor. F1000Res. 2018 Jan 23;7:96. doi: 10.12688/f1000research.13056.1. eCollection, 2018. PMID:29416854 doi:http://dx.doi.org/10.12688/f1000research.13056.1
  2. Huang RH, Fremont DH, Diener JL, Schaub RG, Sadler JE. A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure. 2009 Nov 11;17(11):1476-84. PMID:19913482 doi:10.1016/j.str.2009.09.011

1. Desch, K. C. (2018). Regulation of plasma von Willebrand factor. F1000Research, 7, 96. http://doi.org/10.12688/f1000research.13056.1

2. Huang, R.-H., Fremont, D. H., Diener, J. L., Schaub, R. G., & Sadler, J. E. (2009). A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1. Structure (London, England : 1993), 17(11), 10.1016/j.str.2009.09.011. http://doi.org/10.1016/j.str.2009.09.011

3. Echahdi, H., El Hasbaoui, B., El Khorassani, M., Agadr, A., & Khattab, M. (2017). Von Willebrand’s disease: case report and review of literature. The Pan African Medical Journal, 27, 147. http://doi.org/10.11604/pamj.2017.27.147.12248

4. Jakobi, A. J., Mashaghi, A., Tans, S. J., & Huizinga, E. G. (2011). Calcium modulates force sensing by the von Willebrand factor A2 domain. Nature Communications, 2, 385–. http://doi.org/10.1038/ncomms1385

5. Lenting, P. J., Christophe, O. D., & Denis, C. V. (2015). von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood, 125(13), 2019-2028. Accessed May 01, 2018. https://doi.org/10.1182/blood-2014-06-528406.

6. Peyvandi, F., Garagiola, I., & Baronciani, L. (2011). Role of von Willebrand factor in the haemostasis. Blood Transfusion, 9(Suppl 2), s3–s8. http://doi.org/10.2450/2011.002S

Personal tools